The stock of Tharimmune Inc (THAR) has seen a -11.50% decrease in the past week, with a -8.68% drop in the past month, and a -28.32% decrease in the past quarter. The volatility ratio for the week is 10.57%, and the volatility levels for the past 30 days are at 16.85% for THAR. The simple moving average for the last 20 days is -15.56% for THAR stock, with a simple moving average of -51.36% for the last 200 days.
Is It Worth Investing in Tharimmune Inc (NASDAQ: THAR) Right Now?
The 36-month beta value for THAR is also noteworthy at 1.40. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for THAR is 1.45M, and at present, short sellers hold a 34.27% of that float. The average trading volume of THAR on November 18, 2024 was 1.03M shares.
THAR) stock’s latest price update
The stock price of Tharimmune Inc (NASDAQ: THAR) has plunged by -7.83 when compared to previous closing price of 2.17, but the company has seen a -11.50% decline in its stock price over the last five trading sessions. accesswire.com reported 2024-11-18 that Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events Phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025 BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented new TH104 clinical data at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024, underway in San Diego from November 15-19. The Phase 1 trial was a single-dose, single-center, open-label, randomized study of TH104 transmucosal buccal film conducted in two cohorts of patients with chronic liver disease (CLD), with the primary outcome of safety and tolerability.
THAR Trading at -17.59% from the 50-Day Moving Average
After a stumble in the market that brought THAR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.49% of loss for the given period.
Volatility was left at 16.85%, however, over the last 30 days, the volatility rate increased by 10.57%, as shares sank -7.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.31% lower at present.
During the last 5 trading sessions, THAR fell by -11.95%, which changed the moving average for the period of 200-days by -69.85% in comparison to the 20-day moving average, which settled at $2.37. In addition, Tharimmune Inc saw -73.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at THAR starting from Appajosyula Sireesh, who purchase 5,000 shares at the price of $2.02 back on Nov 13 ’24. After this action, Appajosyula Sireesh now owns 10,758 shares of Tharimmune Inc, valued at $10,096 using the latest closing price.
MILBY RANDY, the CEO of Tharimmune Inc, purchase 2,500 shares at $2.09 during a trade that took place back on Oct 08 ’24, which means that MILBY RANDY is holding 12,934 shares at $5,221 based on the most recent closing price.
Stock Fundamentals for THAR
The total capital return value is set at -3.68. Equity return is now at value -454.53, with -257.79 for asset returns.
Currently, EBITDA for the company is -9.3 million with net debt to EBITDA at 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.30.
Conclusion
In summary, Tharimmune Inc (THAR) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
